Edesa Biotech Highlights Upcoming Conference Schedule
Edesa Biotech, Inc. (Nasdaq: EDSA), a leading clinical-stage biopharmaceutical company dedicated to developing therapeutics for immuno-inflammatory diseases, is excited to announce its participation in several prestigious upcoming conferences. This engagement offers a significant opportunity to connect with industry leaders, investors, and health professionals to discuss the latest advancements in medical dermatology and respiratory therapies.
Participating Conferences
The management team at Edesa, alongside key business development staff, will actively engage in the following significant industry events:
- BIO-Europe, Stockholm, Sweden, November 4-6
- Dermatology Drug Development Summit, Boston, Massachusetts, November 12-14
- LSX Investival Showcase, London, UK, November 18
These conferences present vital platforms for Edesa Biotech to showcase its innovative research, connect with potential partners, and foster discussions on advancing treatments for inflammatory diseases.
Opportunities to Connect
For interested parties wishing to schedule a meeting with Edesa Biotech during these conferences, it is encouraged to reach out to the conference organizers or to the company directly through their contact information.
Company Overview: Innovating Inflammatory Disease Treatments
Edesa Biotech, Inc. focuses on delivering innovative solutions for inflammatory and immune-related diseases. Currently, they are advancing a robust clinical pipeline that emphasizes two key therapeutic areas: Medical Dermatology and Respiratory conditions.
Promising Pipeline in Medical Dermatology
In the realm of Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody aimed at treating vitiligo, a prevalent autoimmune disorder that causes loss of skin color. Furthermore, the company is advancing EB01, a 1.0% daniluromer cream designed for moderate-to-severe chronic Allergic Contact Dermatitis (ACD), which is recognized as a common skin condition linked with occupational exposure.
Advancements in Respiratory Treatments
When addressing respiratory concerns, Edesa’s flagship candidate, EB05 (paridiprubart), is currently being evaluated in a government-funded platform study for its efficacy in treating Acute Respiratory Distress Syndrome (ARDS). This severe condition, marked by reduced oxygen delivery, poses significant health risks, and Edesa is dedicated to making strides in this crucial area.
Additionally, Edesa is preparing to submit an investigational new drug application (IND) for EB07, aiming to initiate a Phase 2 study pertaining to pulmonary fibrosis—an area where innovative treatments are urgently needed.
Staying Updated with Edesa Biotech
To stay informed about Edesa’s progress, developments, and conference activities, interested individuals can sign up for news alerts directly through their website. The company actively shares updates across their social media platforms, allowing followers to engage with their latest news and insights.
Contact Information
For more information, or to schedule a discussion at one of the upcoming conferences, individuals are encouraged to connect with:
Gary Koppenjan
Edesa Biotech, Inc.
(289) 800-9600
investors@edesabiotech.com
Frequently Asked Questions
What conferences is Edesa Biotech participating in?
Edesa Biotech will participate in BIO-Europe, Dermatology Drug Development Summit, and LSX Investival Showcase.
What are the focus areas of Edesa's clinical pipeline?
The clinical pipeline focuses on Medical Dermatology and Respiratory conditions.
How can one schedule a meeting with Edesa during the conferences?
Individuals can schedule meetings through conference organizers or directly via Edesa's contact information.
What condition is the drug EB05 targeting?
EB05 is being evaluated as a treatment for Acute Respiratory Distress Syndrome (ARDS).
Who can be contacted for more information about Edesa Biotech?
Gary Koppenjan is the contact person for inquiries regarding Edesa Biotech.
